CSL Limited

ASX:CSL Stock Report

Market Cap: AU$136.7b

CSL Valuation

Is CSL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CSL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CSL (A$278.79) is trading below our estimate of fair value (A$418.48)

Significantly Below Fair Value: CSL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CSL?

Key metric: As CSL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CSL. This is calculated by dividing CSL's market cap by their current earnings.
What is CSL's PE Ratio?
PE Ratio31.8x
EarningsUS$2.64b
Market CapUS$85.09b

Price to Earnings Ratio vs Peers

How does CSL's PE Ratio compare to its peers?

The above table shows the PE ratio for CSL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average60.2x
TLX Telix Pharmaceuticals
174.7x38.3%AU$8.6b
CUV Clinuvel Pharmaceuticals
16.7x26.2%AU$599.4m
REGN Regeneron Pharmaceuticals
16.5x7.0%US$79.6b
AMGN Amgen
32.9x18.5%US$143.0b
CSL CSL
31.8x13.0%AU$136.7b

Price-To-Earnings vs Peers: CSL is good value based on its Price-To-Earnings Ratio (31.8x) compared to the peer average (60.3x).

Price to Earnings Ratio vs Industry

How does CSL's PE Ratio compare vs other companies in the Global Biotechs Industry?

18 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CSL 31.8xIndustry Avg. 26.5xNo. of Companies18PE020406080100+
18 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CSL is expensive based on its Price-To-Earnings Ratio (31.8x) compared to the Global Biotechs industry average (26.5x).

Price to Earnings Ratio vs Fair Ratio

What is CSL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CSL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.8x
Fair PE Ratio32x

Price-To-Earnings vs Fair Ratio: CSL is good value based on its Price-To-Earnings Ratio (31.8x) compared to the estimated Fair Price-To-Earnings Ratio (32x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CSL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$278.79
AU$340.66
+22.2%
5.8%AU$372.63AU$297.73n/a15
Dec ’25AU$282.22
AU$331.86
+17.6%
5.9%AU$356.90AU$285.16n/a15
Nov ’25AU$281.62
AU$328.51
+16.7%
6.2%AU$353.95AU$278.93n/a15
Oct ’25AU$288.21
AU$313.32
+8.7%
6.4%AU$346.82AU$266.76n/a14
Sep ’25AU$307.16
AU$309.83
+0.9%
9.6%AU$343.65AU$223.28n/a15
Aug ’25AU$310.59
AU$322.16
+3.7%
9.6%AU$367.17AU$232.31n/a15
Jul ’25AU$292.60
AU$307.61
+5.1%
8.2%AU$331.43AU$227.07n/a16
Jun ’25AU$280.10
AU$306.71
+9.5%
8.2%AU$334.06AU$228.87n/a16
May ’25AU$274.49
AU$305.66
+11.4%
9.4%AU$339.01AU$232.45n/a16
Apr ’25AU$287.92
AU$303.83
+5.5%
9.0%AU$341.20AU$232.95n/a16
Mar ’25AU$282.35
AU$301.50
+6.8%
9.0%AU$334.83AU$231.44n/a16
Feb ’25AU$296.76
AU$321.83
+8.4%
6.3%AU$352.41AU$278.23n/a15
Jan ’25AU$286.65
AU$308.65
+7.7%
4.3%AU$343.39AU$288.82n/a16
Dec ’24AU$262.86
AU$311.54
+18.5%
4.1%AU$349.56AU$294.01AU$282.2216
Nov ’24AU$234.98
AU$323.64
+37.7%
4.8%AU$361.36AU$300.30AU$281.6216
Oct ’24AU$250.80
AU$328.43
+31.0%
4.0%AU$361.13AU$300.11AU$288.2116
Sep ’24AU$269.09
AU$326.82
+21.5%
5.8%AU$360.64AU$270.09AU$307.1618
Aug ’24AU$269.32
AU$325.65
+20.9%
6.2%AU$352.98AU$261.58AU$310.5918
Jul ’24AU$277.38
AU$326.90
+17.9%
6.2%AU$349.81AU$259.04AU$292.6018
Jun ’24AU$310.29
AU$352.10
+13.5%
6.9%AU$376.39AU$265.34AU$280.1018
May ’24AU$302.43
AU$338.98
+12.1%
7.1%AU$361.57AU$254.89AU$274.4917
Apr ’24AU$288.30
AU$341.11
+18.3%
7.0%AU$365.29AU$257.73AU$287.9217
Mar ’24AU$292.85
AU$340.93
+16.4%
7.1%AU$362.93AU$256.06AU$282.3517
Feb ’24AU$301.52
AU$314.46
+4.3%
7.7%AU$345.52AU$248.58AU$296.7616
Jan ’24AU$287.76
AU$319.60
+11.1%
6.4%AU$347.91AU$265.12AU$286.6516
Dec ’23AU$298.66
AU$309.44
+3.6%
6.2%AU$338.25AU$260.23AU$262.8616

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 07:04
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

CSL Limited is covered by 31 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Russell WrightAPP Securities Pty Ltd.
Russell WrightBarclay Pearce Capital Pty Limited
Saul HadassinBarrenjoey Markets Pty Limited